Anti-inflammatory agents in the treatment of diabetes and its vascular complications

Rena M. Pollack, Marc Y. Donath, Derek LeRoith, Gil Leibowitz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

197 Scopus citations


The association between hyperglycemia and inflammation and vascular complications in diabetes is now well established. Antidiabetes drugs may alleviate inflammation by reducing hyperglycemia; however, the anti-inflammatory effects of these medications are inconsistent and it is unknown whether their beneficial metabolic effects are mediated via modulation of chronic inflammation. Recent data suggest that immunomodulatory treatments may have beneficial effects on glycemia, b-cell function, and insulin resistance. However, the mechanisms underlying their beneficial metabolic effects are not always clear, and there are concerns regarding the specificity, safety, and efficacy of immune-based therapies. Herein, we review the anti-inflammatory and metabolic effects of current antidiabetes drugs and of anti-inflammatory therapies that were studied in patients with type 2 diabetes.Wediscuss the potential benefit of using anti-inflammatory treatments in diabetes and important issues that should be addressed prior to implementation of such therapeutic approaches.

Original languageAmerican English
Pages (from-to)S244-S252
JournalDiabetes Care
StatePublished - 1 Aug 2016
Externally publishedYes


Dive into the research topics of 'Anti-inflammatory agents in the treatment of diabetes and its vascular complications'. Together they form a unique fingerprint.

Cite this